Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
about
Trial watch: Dendritic cell-based anticancer therapyPhotodynamic therapy of tumors can lead to development of systemic antigen-specific immune responseStrategies and challenges in eliciting immunity to melanoma.Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities.Selected climatic variables and blood pressure in Central European patients with chronic renal failure on haemodialysis treatment.Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myelomaMurine dendritic cells pulsed in vitro with Toxoplasma gondii antigens induce protective immunity in vivoCell-based vaccines for the stimulation of immunity to metastatic cancers.New technologies toward dendritic cell-based cancer immunotherapies.Heme oxygenase-1 expression in murine dendritic cell subpopulations: effect on CD8+ dendritic cell differentiation in vivo.Dendritic cells crosspresent antigens from live B16 cells more efficiently than from apoptotic cells and protect from melanoma in a therapeutic model.An overview of cancer immunotherapy.Feeding dendritic cells with tumor antigens: self-service buffet or à la carte?RNA-transfected dendritic cells in cancer immunotherapy.The nanomaterial-dependent modulation of dendritic cells and its potential influence on therapeutic immunosuppression in lupus.Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens.RNA as a tumor vaccine: a review of the literature.Progress on new vaccine strategies for the immunotherapy and prevention of cancer.T-cell-directed cancer vaccines: the melanoma model.Recent advances in dendritic cell vaccines for cancer treatment.Strategies for designing and optimizing new generation vaccines.Immunotherapy for melanoma.Spinning molecular immunology into successful immunotherapy.Dendritic cell-based vaccines: barriers and opportunitiesAugmentation of antitumor immunity by fusions of ethanol-treated tumor cells and dendritic cells stimulated via dual TLRs through TGF-β1 blockade and IL-12p70 production.Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells.Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization.Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas.Antigen-loaded dendritic cell migration: MR imaging in a pancreatic carcinoma model.Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response.Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells.Immunotherapy of cancer by active vaccination: does allogeneic bone marrow transplantation after non-myeloablative conditioning provide a new option?Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth.The evolving role of monoclonal antibodies and dendritic cell therapy in hematologic malignancies.Role of dendritic cells in immunopathogenesis of human immunodeficiency virus infectionMHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cellsHuman non-germinal center B cell interleukin (IL)-12 production is primarily regulated by T cell signals CD40 ligand, interferon gamma, and IL-10: role of B cells in the maintenance of T cell responses.Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes.The new vaccines: building viruses that elicit antitumor immunity.Antigen presentation in retroviral vector-mediated gene transfer in vivo.
P2860
Q27024047-D552642A-667F-41DC-9A0B-C6ED8D0A58B2Q28744245-E68EDD05-6A8A-4F0E-9C2F-E4361AAAF267Q30435893-36CF50D5-48F6-42D2-890A-B5DD73D9A24EQ30863574-2693270D-88B6-47B0-8818-17228045866DQ33433723-7FAC3C67-46D8-497E-8A60-9A5B9FFC4EEAQ33732491-D749B285-0896-4C69-8064-D91AC80BBFFBQ33765923-2B13E604-9807-4511-97EA-4030971CAD26Q33776134-842EA38D-0D6D-43E6-B333-C3AD3E58BD82Q33817903-30CA2CF8-EC95-4F71-B046-7B9153E17CEFQ33882483-E609A21E-7F6E-4BED-9635-07667BB489CEQ33892712-91D57CBC-4BAD-46E7-9D24-A6FE10282502Q33940388-5ACBD3BC-580E-4A92-9A23-1FC525C26FFEQ33986125-27A736F3-88A3-4721-8679-70C2DDCDEE67Q34078072-F226078A-4B01-4410-9706-54E7283D0471Q34180779-4D315D03-F25A-473A-A769-23FD7698150DQ34265381-4082712C-DB56-470A-9A71-8B724A337201Q34266409-86A4ABF5-6EB4-4865-9CBB-FA55C5AFE721Q34328457-3AE2245F-4757-484A-8C34-B4A2F729E031Q34452071-A84555D4-6CEE-47D6-84D2-AA7341A4D72CQ34480504-3104D6DC-652A-4098-8BDF-85E2565265E4Q34572198-6FD7CBBF-466E-4BED-A401-9A1612624465Q34573035-1D00988D-B691-44F0-B528-11D51331320CQ34632056-B35101B0-11B0-46D9-958C-30882689249BQ34661797-106247CA-A109-4802-A48E-4802C2D3FB48Q34744217-C29CAE10-CC86-45B5-B376-7348DB9E7C3AQ34792069-8F2348CD-6121-415F-A1A7-D943AD3E2F52Q34801021-4A73DD3D-5C08-4999-9B4C-77975A7B81ACQ34912810-68CEB058-AB53-418A-B4DF-A27FE167BE0DQ35038974-B0FE669A-43B1-4E48-92C7-1848781F37FDQ35050844-0D7C7594-B12C-477B-AF98-9774C73033F3Q35079643-F8B91341-1FEB-460B-B64F-A552934BA1D5Q35142329-30A3DD69-3E68-4A18-9C76-1AE6AB196CD0Q35159565-771CDC23-A080-49FA-A01A-5BE0F7AE4611Q35173179-7A895E4F-47FD-4F62-B351-C36456084DA6Q35374250-C92F86D1-A0B5-49D2-8132-C3A7E09D2017Q35573814-5D8C53E2-5386-42CC-BFB0-37A92ACE2F45Q35834633-B8FEC7F0-FD54-4017-AD2C-F2C9C49E3BBBQ35922431-0B210B3F-EF8F-46AE-83EB-BF53C7141897Q35946203-3B813A3C-55D4-4E2F-9FF6-4D5AC07133D2Q36029106-D7286A5F-F0F3-44CC-98C7-E4C3BFBF0B82
P2860
Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Murine dendritic cells loaded ...... against tumor antigen in vivo
@ast
Murine dendritic cells loaded ...... against tumor antigen in vivo
@en
type
label
Murine dendritic cells loaded ...... against tumor antigen in vivo
@ast
Murine dendritic cells loaded ...... against tumor antigen in vivo
@en
prefLabel
Murine dendritic cells loaded ...... against tumor antigen in vivo
@ast
Murine dendritic cells loaded ...... against tumor antigen in vivo
@en
P2860
P50
P356
P1476
Murine dendritic cells loaded ...... against tumor antigen in vivo
@en
P2093
P2860
P304
P356
10.1084/JEM.183.1.317
P407
P577
1996-01-01T00:00:00Z